166 related articles for article (PubMed ID: 35835581)
21. [Lymphoma in children and adolescents].
Sorge I; Georgi TW; Hirsch FW
Radiologe; 2021 Jul; 61(7):611-618. PubMed ID: 34160645
[TBL] [Abstract][Full Text] [Related]
22. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG PET/CT Imaging of Primary Gastric Lymphoma.
Davis BS; Thompson TA; Wolin EA
J Nucl Med Technol; 2016 Dec; 44(4):263-264. PubMed ID: 27493260
[TBL] [Abstract][Full Text] [Related]
24. Current Role of Functional Imaging in the Management of Lymphoma.
Cheson BD; Meignan M
Curr Oncol Rep; 2021 Nov; 23(12):144. PubMed ID: 34735647
[TBL] [Abstract][Full Text] [Related]
25. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
26. Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging.
Giraudo C; Karanikas G; Weber M; Raderer M; Jaeger U; Simonitsch-Klupp I; Mayerhoefer ME
J Magn Reson Imaging; 2018 May; 47(5):1217-1226. PubMed ID: 29086453
[TBL] [Abstract][Full Text] [Related]
27. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW
Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335
[TBL] [Abstract][Full Text] [Related]
28. Diffusion-weighted MRI for initial staging in Hodgkin`s lymphoma: comparison with FDG PET.
Winzer R; Hoberück S; Zöphel K; Kotzerke J; Brauer T; Hoffmann RT; Platzek I
Eur J Radiol; 2020 Feb; 123():108775. PubMed ID: 31864143
[TBL] [Abstract][Full Text] [Related]
29. Value of staging information provided by linear-array endoscopic ultrasound for therapeutic response and prognosis prediction in gastric lymphoma.
Tingyu H; Jianqiang L; Zuguang X; Xiujiang Y; Ke C
Dig Endosc; 2021 Sep; 33(6):929-938. PubMed ID: 33124105
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
Mistry V; Scott JR; Wang TY; Mollee P; Miles KA; Law WP; Hapgood G
Cancer Imaging; 2023 Jan; 23(1):11. PubMed ID: 36694244
[TBL] [Abstract][Full Text] [Related]
31. 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography in primary extranodal lymphomas: treatment response evaluation and prognosis.
Salvatore B; Fonti R; De Renzo A; Pellegrino S; Ferrara IL; Mainolfi CG; Marano L; Selleri C; Pane F; Del Vecchio S; Pace L
Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):219-225. PubMed ID: 29697219
[TBL] [Abstract][Full Text] [Related]
32. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography for detection and staging of malignant lymphoma.
Buchmann I; Moog F; Schirrmeister H; Reske SN
Recent Results Cancer Res; 2000; 156():78-89. PubMed ID: 10802866
[TBL] [Abstract][Full Text] [Related]
34. The role of 18F-FDG PET and PET/CT in the evaluation of primary cutaneous lymphoma.
Qiu L; Tu G; Li J; Chen Y
Nucl Med Commun; 2017 Feb; 38(2):106-116. PubMed ID: 27792043
[TBL] [Abstract][Full Text] [Related]
35. Early evaluation of tumor response to
Kitajima K; Okada M; Kashiwagi T; Yoshihara K; Tokugawa T; Sawada A; Yoshihara S; Fujimori Y; Yamakado K
Eur Radiol; 2019 Jul; 29(7):3935-3944. PubMed ID: 30899979
[TBL] [Abstract][Full Text] [Related]
36. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.
Thanarajasingam G; Bennani-Baiti N; Thompson CA
Curr Treat Options Oncol; 2016 May; 17(5):24. PubMed ID: 27032646
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of interim PET/CT in non-hodgkin lymphoma].
Guevara DL; Bernard S; Manhood S; Melani S; Yerovi F; Rodríguez MLÁ
Rev Med Chil; 2020 Nov; 148(11):1558-1567. PubMed ID: 33844761
[TBL] [Abstract][Full Text] [Related]
38. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
[TBL] [Abstract][Full Text] [Related]
39. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma.
Kotzerke J; Guhlmann A; Moog F; Frickhofen N; Reske SN
Eur J Nucl Med; 1999 Jan; 26(1):31-8. PubMed ID: 9933659
[TBL] [Abstract][Full Text] [Related]
40. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
